SOLICITATION NOTICE
B -- Cell Signaling and Mouse Models of Cancer Consultant
- Notice Date
- 8/17/2009
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90170-MM
- Archive Date
- 9/15/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Molecular Biology, plans to procure services regarding cell signaling and mouse models of cancer with Dr. Tadashi Yamamoto, 203, 3-11-17 Ebisu-minami, Shibuya-ka, Tokyo 150-0022, Japan. Period of performance shall be for three months from date of award. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1).The North American Industry Classification System Code is 541690 and the business size standard is $7.0M. Only one award will be made as a result of this solicitation. This will be a firm fixed price type contract. The Laboratory of Molecular Biology, Molecular Biology Section (MBS) develops immunotoxins against cell surface markers to treat various cancers. Preclinical and clinical studies are underway to develop an understanding of the efficacy and limitations of the immunotoxin drugs. The laboratory is also currently characterizing several genes that are associated with cancer or growth regulation, to assess their utility as possible targets of new immunotoxins for cancer therapy. The contractor shall provide services in both cell signaling and mouse models of cancer to evaluate our current research program in growth regulation genes and provide recommendations and guidance directed towards determining whether any of our candidate genes can be developed into targets for immunotoxin therapy. The contractor shall evaluate: 1.)POTE - a primate-specific gene family that encodes cancer testis antigens 2.)CAPC - expressed highly in breast cancer, pancreatic cancer, and colon cancer and many cancer cell lines 3.)Mesothelin - expression in normal human tissues is limited to mesothelial cells that line the pleura, peritoneum and pericardium The MBS is requesting the services of Dr. Tadashi Yamamoto for consulting on our Growth Regulation projects. Dr. Yamamoto is the best consultant to fulfill our requirement for the following reasons: Dr. Yamamoto is Chair of the Department of Cancer Biology at the Institute of Medical Science at the University of Tokyo (IMSUT), Japan's foremost research institute for medical life science. From 2003-2007, Dr. Yamamoto served as Dean of IMSUT after being elected to the position by his 200 colleagues. Dr. Yamamoto is a recognized leader in the field of Cancer Biology. Dr. Yamamoto served as a Visiting Fellow in the MBS in 1977-1981. He is well acquainted with the laboratory's Immunotoxin and Gene Discovery/Growth Regulation research programs. Dr. Yamamoto has published over 300 papers in the fields of cell signaling, cancer biology, and mouse models of cancer. Dr. Yamamoto is an expert in these fields of which we seek counsel. Dr. Yamamoto is on the editorial boards of several prestigious scientific journals, evidence of his recognized experience and expertise in biomedical research. Dr. Yamamoto is a member of Japan's foremost scientific associations. Dr. Yamamoto's expertise in cell signaling, cancer biology and mouse models of cancer, publication history, and leadership experience combined with his understanding of the MBS' research program based on his prior years as a visiting fellow in the MBS make Dr. Yamamoto uniquely qualified to provide the requested services, analyze the laboratory's current research, and provide creative, forward thinking and scientifically sound research options for the laboratory to pursue. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on August 31, 2009. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation No. NCI-90170-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90170-MM/listing.html)
- Record
- SN01914986-W 20090819/090818002157-08986324c2ed761229730f7e155ba9f8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |